Regulatory-Grade RLD & Comparator Sourcing Supporting Cipla's Global Growth, Innovation & Complex Product Development GNH INDIA | TRUSTED COMPARATOR SOURCING PARTNER

STRATEGIC CONTEXT Growth in Complex & Biologic Programmes Demands Stronger Comparator Strategy Cipla's expanding focus across multiple therapeutic areas and regulatory jurisdictions requires a fundamentally different approach to comparator sourcing. The complexity of your development pipeline—from biosimilars to specialty respiratory products—demands regulatory- grade sourcing capabilities that match your innovation ambitions. Complex Generics & Specialty Products Advanced formulations requiring sophisticated analytical and clinical comparator strategies Respiratory & Chronic Therapy Portfolios High-value therapeutic areas with stringent regulatory requirements and competitive timelines Global Regulatory Submissions Parallel filings across FDA, EMA, CDSCO and other markets requiring coordinated documentation Innovation-Led Partnerships Strategic collaborations demanding regulatory excellence and predictable timelines Comparator sourcing is no longer operational—it is a regulatory and commercial success factor.

The Biosimilar & Complex Generic Challenge The regulatory landscape for biosimilar and complex generic development has fundamentally shifted. What regulators accepted five years ago now triggers immediate queries and potential programme delays. Biosimilar developers face intensifying scrutiny at every stage, with comparator documentation becoming a critical success factor that can make or break multi-year development programmes. Intensifying Scrutiny Full traceability and chain-of-custody documentation required from source to administration Access Barriers Innovators actively restricting comparator availability through distribution controls and supply limitations Documentation Gaps Missing Certificate of Pharmaceutical Product, GMP certificates, or Marketing Authorisation proof leads to regulatory queries Rejection Risk Comparator issues identified during review can derail entire programmes, requiring study restarts

BUSINESS IMPACT The Stakes Have Never Been Higher Comparator-related issues represent one of the most significant yet preventable risks in biosimilar development. The financial and competitive implications of getting this wrong extend far beyond the immediate programme delay. Market Opportunity $74B+ Global Biosimilars Market Projected market size by 2030, representing unprecedented growth opportunity $400M Average Programme Investment Typical capital deployed per biosimilar development programme from concept to approval Cost of Failure 6–18 Month Delays Typical timeline extension from comparator-related regulatory queries or clinical holds Competitive Position Lost First-to-market advantage eroded, with late entrants facing 30–40% lower pricing power Study Restart Costs Restarting clinical programmes requires new comparator sourcing, patient recruitment, and regulatory resubmission

Why Biologics Change the Rules Comparator Selection is a Scientific & Regulatory Decision Biologics are fundamentally different from small molecules. Their complexity4large molecular structures, sensitivity to manufacturing conditions, and inherent variability4creates unique challenges that directly impact comparator sourcing strategy. Regulatory authorities understand these complexities and have evolved their expectations accordingly. Comparator selection now requires deep scientific rationale, not just procurement capability.

1. Inherent Complexity Biologics depend on manufacturing process4minor changes can alter efficacy, safety, and immunogenicity profiles
2. Batch Variability Natural lot-to-lot variation requires multi-batch sourcing strategy with documented analytical characterisation
3. Proof Required Regulators demand full analytical and clinical evidence demonstrating comparability, not just bioequivalence
4. Strategic Decision Wrong comparator choice creates long-term risk4cannot be easily corrected once clinical studies commence

2025 REGULATORY STANDARDS Global Regulators Now Expect Regulatory-Grade Comparator Sourcing The regulatory bar has risen dramatically. FDA, EMA, and CDSCO have aligned on core expectations that extend well beyond traditional procurement standards. Authorities now routinely request comprehensive documentation packages that prove authenticity, quality, and regulatory status at the time of use in studies.

1. Authentic Origin Verification Complete pedigree documentation from manufacturer through distribution chain to clinical site, with verified invoices and chain of custody records
2. CPP & GMP Evidence Certificate of Pharmaceutical Product from sourcing country, current Good Manufacturing Practice certificates, and batch- specific Certificate of Analysis
3. Marketing Authorisation Clarity Proof of valid marketing status in source market at time of procurement, including MA holder identity and approval dates
4. Cold Chain Integrity Validated temperature monitoring throughout transport and storage, with documented excursion management protocols Shortcuts that worked five years ago now trigger immediate regulatory questions. The cost of inadequate documentation far exceeds the investment in proper sourcing.

Critical Distinction Regulators Care About "Sourced From" ≠ "Licensed In" This distinction represents one of the most common—and costly—misunderstandings in comparator sourcing. Regulators are increasingly sophisticated in their scrutiny of comparator documentation, and this nuance can determine programme success or failure. Physical Source Location What it means: The country or region where the product was physically purchased, received, or shipped from What it doesn't prove: That the product is legitimately approved and marketed by the correct Marketing Authorisation holder in that jurisdiction Common mistake: Assuming geographic procurement automatically satisfies regulatory requirements Regulatory Licence Holder What it means: The legal entity holding the Marketing Authorisation in the country where regulatory approval exists What regulators verify: That the comparator used in studies matches the approved reference product under the legitimate MA holder's control Critical requirement: Documentation proving MA holder identity and approval status at time of use Regulatory Reality Authorities require proof that the comparator is approved and marketed by the legitimate MA holder, not merely bought in that country. This requires deep understanding of regulatory licensing strategy and global approval landscapes. GNH Expertise: We ensure comparators align with regulatory licensing strategy, not just geography.

The GNH India Difference Built for Regulatory-Grade Comparator Sourcing GNH India's approach to comparator sourcing fundamentally differs from traditional procurement models. We've built our capabilities around regulatory requirements first, with commercial execution designed to support compliance rather than compete with it. Every element of our service4from sourcing strategy consultation through final delivery4is structured to provide the documentation depth and quality assurance that modern biosimilar development demands. Global Sourcing Network Direct access to regulated markets including United States, European Union, and other major regulatory jurisdictions with established supplier relationships Documentation Control Comprehensive regulatory packages including CPP, GMP certificates, batch records, regulatory correspondence4all audit-ready and formatted for submission Complete Pedigree Trail End-to-end chain of custody with validated cold chain management, temperature monitoring, and excursion documentation from source to delivery Regulatory-Ready Packages Dossiers pre-formatted for FDA, EMA, and CDSCO submissions, reducing your regulatory team's burden and accelerating filing timelines Risk mitigation built into every step4from sourcing strategy consultation to final delivery and post-supply documentation support

STRATEGIC VALUE Business Impact for Cipla How This Supports Cipla's Growth & Innovation Programmes Regulatory-grade comparator sourcing delivers value far beyond the immediate procurement transaction. For organisations like Cipla with ambitious global development pipelines and strategic partnership objectives, comparator capability becomes a competitive differentiator and risk mitigation tool. Faster Programme Progression Accelerate complex generic and biosimilar programmes by eliminating comparator-related delays and regulatory queries Reduced Regulatory Risk Minimise likelihood of clinical holds, additional study requirements, or approval delays stemming from comparator documentation gaps Timeline Predictability Improve confidence in global development timelines with reliable comparator sourcing integrated into project planning Stronger Partnership Position Enhance regulatory foundation for licensing discussions and development partnerships, demonstrating operational sophistication to potential partners Internal Resource Optimisation Reduce burden on regulatory and clinical operations teams, allowing them to focus on scientific strategy rather than sourcing logistics

Proposed Engagement A Focused, Low-Risk Way to Start We recommend beginning with a structured, pilot-based approach that demonstrates value whilst minimising organisational disruption. This phased engagement allows both teams to establish working protocols and validate the strategic fit before broader implementation. Preferred Framework Pilot Sourcing Comparator Review This approach provides early proof of value whilst building the foundation for longer-term strategic partnership around your complex and biosimilar development pipeline.

1. Comparator Sourcing Review Consultative review of upcoming development programmes to identify regulatory-grade sourcing requirements and potential risk areas
2. Pilot Sourcing Engagement Execute one clinical or registration project end-to-end, demonstrating documentation quality and delivery reliability
3. Preferred Framework Establish ongoing regulatory-grade comparator sourcing partnership with defined protocols and service level agreements GNH India — Enabling confident, compliant, and accelerated global development